OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

Company Performance - OrganiGram reported a quarterly loss of $0.03 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.01, marking an earnings surprise of -200.00% [1] - The company posted revenues of $51.16 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.86%, and showing a significant increase from $30.01 million in the same quarter last year [2] - Over the last four quarters, OrganiGram has not surpassed consensus EPS estimates, but it has topped consensus revenue estimates three times [2] Stock Performance - OrganiGram shares have declined approximately 1.2% since the beginning of the year, contrasting with the S&P 500's gain of 9.6% [3] - The current Zacks Rank for OrganiGram is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $49.86 million, and for the current fiscal year, it is $0.07 on revenues of $170.56 million [7] - The trend of estimate revisions for OrganiGram was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Products industry, to which OrganiGram belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may impact the stock's performance [8] - The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]